IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase 3positiveIMDELLTRAIMFINZIPositive
AI Analysis
Summary
Amgen announced that IMDELLTRA combined with IMFINZI demonstrated a highly significant overall survival benefit in the Phase 3 DeLLphi-305 study for first-line extensive stage small cell lung cancer, also meeting secondary endpoints for progression-free survival and objective response rate.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
DeLLphi-305 study demonstrated highly significant and clinically meaningful overall survival benefit with IMDELLTRA in combination with IMFINZI versus durvalumab alone. Met secondary endpoints of progression-free survival and objective response rate.
Importance:9/10
Sentiment:
0.95
oncologysmall cell lung cancerimmunotherapycombination therapyPhase 3positive data
Related Companies
Read the original article
Published by PR Newswire Biotech on September 8, 2026 1:00 PM